| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Departments of Internal Medicine, Division of Molecular Oncology,1 Cell Biology and Physiology,2 Cancer Biology Pathway, Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri 631103
Received 20 March 2007/ Returned for modification 11 May 2007/ Accepted 14 November 2007
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Approximately half of the cell's energy expenditure is directed toward ribosome biogenesis (26). The nucleolus, long recognized as a marker for active cellular growth, was first described in the early 1960s as the center of ribosomal DNA (rDNA) transcription and ribosome biogenesis (6, 32). This organelle is composed of three regions, on the basis of morphology at the ultrastructural level: the fibrillar centers, the dense fibrillar compartment, and the granular zone. rDNA transcription occurs in the junction region between the fibrillar centers and the surrounding dense fibrillar component, and the resulting rRNA is further processed in the periphery of the dense fibrillar component. Further posttranscriptional modifications and assembly into subunits occur in the surrounding granular region (18).
While the primary mechanisms regulating these processes have been well studied in Saccharomyces cerevisiae (13), multicellular organisms demand more complex regulatory mechanisms, in that proliferative capacity is determined not only by the relative abundance of nutrients but also by complicated extracellular signals and growth factors. Indeed, previous studies have demonstrated convergence between the growth and the proliferation pathways via regulation of the tumor suppressor gene products Rb and p53 (9, 17, 43, 48). Both products are known to negatively regulate the activity of polymerase I in rDNA transcription. Oncogenes such as c-Myc also regulate the transcription of rDNA and the genes that encode ribosomal proteins, implying that an intricate network exists within the nucleolus to ensure the proper synthesis of ribosomes (7, 15, 16).
The tumor suppressor p19ARF represents an attractive candidate for coupling proliferation to growth. Given its nucleolar localization (39, 44, 45) and potent induction by hyperproliferative signals (19, 20, 31, 50), ARF represents a potential nucleolar integrator of growth signals coming into the cell. It has been regarded classically as an activator of p53 through its ability to sequester Mdm2, the E3 ubiquitin ligase for p53, in the nucleolus (39, 44, 45). However, recent data have demonstrated a role for ARF in binding to and affecting the function of the ribosomal chaperone nucleophosmin (NPM), independent of its ability to regulate p53 (4, 8, 21). Furthermore, these data are consistent with those from a growing number of studies with mice and humans that describe p53-independent functions for ARF tumor suppression (35).
Given ARF's nucleolar localization, its role in suppressing cellular growth and proliferation, and its ability to bind to a protein involved in ribosome biogenesis, we were inclined to explore the functional and physiological consequences of ARF disruption of growth and ribosome biogenesis. Through in vitro and in vivo assays, we utilized targeted Arf knockout mice and selective ARF knockdown via lentiviral RNA interference. Cells derived from Arf-null mice displayed significant alterations in gross nucleolar morphology and abundance and had a marked increase in basal protein synthesis levels compared to that in wild-type cells. Furthermore, this increase in protein synthesis was correlated to increased ribosome biogenesis and cytoplasmic ribosome content, implying a regulatory role for ARF in these processes. Importantly, though ARF levels are nearly undetectable in low-passage mouse embryonic fibroblasts (19), the knockdown of endogenous ARF via short hairpin RNA (shRNA) constructs mimicked the Arf-null nucleolar and ribosomal phenotype, implying an important ribosome homeostatic role for basal ARF proteins in wild-type cells. The progrowth phenotype of the Arf loss was not limited to proliferating cells, as fully differentiated osteoclasts from Arf-null mice exhibited tremendous gains in protein synthesis and overall activity in vivo. Mechanistically, all of the ribosome gains exhibited by the loss of Arf were reversed by the removal of the nucleolar NPM proto-oncogene, indicating that NPM, when untethered from ARF, promotes unrestrained ribosome biogenesis. Taken together, these data strongly argue for a moment-to-moment "thermostat"-like role for basal ARF molecules in controlling NPM-directed ribosome biogenesis and protein synthetic rates.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Cell culture, reagents, and antibodies.
Low-passage (2-5) MEFs were isolated and maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 10 µg/ml gentamicin, 1x nonessential amino acids, 1 mM sodium pyruvate, and 2 mM glutamine. Rabbit anti-p16INK4A (sc-1207), goat anti-
-tubulin (catalog no. sc-7396), and rabbit anti-Myc (catalog no. sc-764) were purchased from Santa Cruz Biotechnology. Rat anti-p19ARF (catalog no. NB 200-169A) was purchased from Novus Biologicals. Mouse anti-NPM (catalog no. 32-5200) was purchased from Zymed.
Plasmid constructs. pLKO-GFP, a lentiviral shRNA expression vector was a generous gift from Sheila Stewart (Washington University). To construct the ARF shRNA vector, pLKO-GFP was digested with AgeI/MluI, and annealed oligonucleotides containing the shRNA target (nucleotides 157 to 177 of exon 1β of p19ARF) or a scrambled control were cloned into these sites. The resultant clones were verified by sequencing. The oligonucleotides used were small interfering ARF (siARF) sense (5'-CCGGGCTCTGGCTTTCGTGAACATGCTCGAGCATGTTCACGAAAGCCAGAGCTTTTTA-3'), siARF antisense (5'-CGCGTAAAAAGCTCTGGCTTTCGTGAACATGCTCGAG CATGTTCACGAAAGCCAGAGC-3'), siScrambled sense (5'-CCGGTACG ACCTGAACTGCTTAGGACTCGAGTCCTAAGCAGTTCAGGTCGTATTTTTA-3'), and siScrambled antisense (5'-CGCGTAAAAATACGACCTGAACTGCTTAGGACTCGAGTCCTAAGCAGTTCAGGTCGTA-3'). The underlined portions represent the 21 nucleotide hairpin sense and antisense strands. For NPM knockdown, annealed oligonucleotides were cloned as described above into pLKO-GFP, the sequences of which were previously reported (27). RNA interference for endogenous c-Myc was performed with siRNAs recognizing the 3' untranslated region (UTR) of c-Myc (5'-AACGTTTATAACAGTTACAAA-3' [Qiagen]). Myc-ER retrovirus was generated and used to infect wild-type and Arf-null MEFs as previously described (50).
AgNOR staining. MEFs were seeded onto glass coverslips overnight and were fixed and stained the following day. A silver nucleolar organizing region (AgNOR) staining method was modified from the protocol presented by Aubele et al. (1). Briefly, cells were fixed in 2% glutaraldehyde, followed by a postfixation in a 3:1 ethanol-acetic acid solution. Cells were stained with a 0.33% formic acid-33.3% silver nitrate solution in 0.66% gelatin and mounted on slides with Vectashield (Vector Labs).
Histomorphometry. Histomorphometric analysis was performed with OsteoQuant Nova Prime software (Bioquant Image Analysis Corp.) on images captured at x200 magnification by an Optitronics Magnifire camera on a Nikon TE300 microscope. Total numbers and total areas (µm2) of AgNOR regions per nucleus from 100 nuclei were assessed, and statistical significance was determined using Student's t test.
Electron microscopy. Asynchronously growing wild-type and Arf–/– MEFs were trypsinized and fixed with 2% glutaraldehyde in phosphate-buffered saline for 10 min. Samples were further processed by the Washington University Department of Cell Biology's Electron Microscopy Core. Pictures of nuclei and nucleoli were taken at magnifications of x3,000 and x7,000, respectively.
[35S]methionine incorporation assay. Cells (1 x 105) were seeded in triplicate and then starved of methionine and cysteine. Cells were pulsed with 14.3 µCi of [35S]methionine (Amersham) and then immediately washed twice with cold phosphate-buffered saline and lysed with 1% Triton X-100 buffer. Total protein was precipitated from lysates with 10% trichloroacetic acid. Pellets were subjected to liquid scintillation counting to measure the incorporated counts per minute.
Ribosome fractionation. Cells (2 x 106) were treated with 50 µg/ml cycloheximide prior to trypsinization and lysis, and fractionation was carried out over a 10 to 45% sucrose gradient (46). Gradients were fractionated, and RNA absorbance at 254 nm was monitored continuously to detect ribosomal subunits.
Lentiviral production and infection.
293T cells (5 x 105) were transfected with 1 µg of pLKO-GFP containing either scrambled or ARF shRNA cassettes along with the pHR8.2
R packaging vector and the pCMV-VSV-G envelope vector. Viral supernatants were collected and pooled. Wild-type MEFs (8 x 105) were plated and infected with viral supernatant containing 10 µg/ml protamine sulfate. Cells were infected again on the following day, checked for green fluorescent protein expression, and allowed to express the shRNA construct for 48 h.
Serum assays. Levels of tartrate-resistant acid phosphatase (TRAP) 5b were measured in serum collected from wild-type or Arf–/– mice, using a TRAP 5b enzyme-linked immunosorbent assay (ELISA) system (IDS, Fountain Hills, AZ).
Osteoclast formation assays.
Whole bone marrow was extracted from femurs and tibias of wild-type or Arf–/– mice and plated in CMG-14-12 culture supernatant (1/10 vol) in
-minimal essential medium (
-MEM) containing 10% fetal calf serum (FCS) to generate primary bone marrow macrophages (BMM), as described previously (49). Cells were fed every day with
-MEM containing 10% FCS, CMG-14-12 supernatant (1/20 vol), and glutathione S-transferase-RANK ligand (GST-RANKL) (100 ng/ml) and incubated for 5 days to generate osteoclasts (49). TRAP staining was performed according to the manufacturer's instructions (Sigma-Aldrich, St. Louis, MO). Five fields at a magnification of x4 were captured with the Magnafire system, and the TRAP-positive cells with three or more nuclei were counted by one blinded to the genotype. A quantitative TRAP solution assay was performed by adding a colorimetric substrate, 5.5 mM p-nitrophenyl phosphate, in the presence of 10 mM sodium tartrate at pH 4.5.
Macrophage proliferation assays.
BMMs (1 x 104) were plated in
-MEM containing 10% FCS and CMG-14-12 supernatant (1/10 vol). Cells were starved in
-MEM containing 0.1% FCS for 12 h. At this time,
-MEM containing 10% FCS and CMG-14-12 supernatant (1/10 vol) was added back to the cells. Cells were labeled with bromodeoxyuridine (BrdU) for 24 h, and proliferation was measured using the chemiluminescent cell proliferation ELISA (Roche Diagnostics, Mannheim, Germany).
Western blotting and serial immunoprecipitation.
MEF cell extracts (30 µg) were loaded onto 4 to 20% sodium dodecyl sulfate (SDS)-polyacrylamide gels (ISC Biosciences), transferred to polyvinylidene difluoride membrane (Millipore), and probed with antibody to rat anti-p19ARF (Novus Biologicals), goat anti-
-tubulin (Santa Cruz Biotechnology), rabbit anti-Myc (Santa Cruz Biotechnology), rabbit anti-p16INK4A (Santa Cruz Biotechnology), and rabbit anti-L5 (ILAMM). Secondary horseradish peroxidase-conjugated anti-rabbit, anti-goat, or anti-rat antibodies (Jackson ImmunoResearch) and ECL+ (Amersham) were used to visualize the bands. For serial immunoprecipitation, 200 µg of wild-type MEF lysate was immunoprecipitated with GammaBind (Amersham) by a custom-made rabbit NPM polyclonal antibody (Sigma Genosys) (46). The final supernatant was concentrated with a Vivaspin column (Vivascience), and all samples were loaded onto 10% SDS-polyacrylamide gels for immunoblotting analysis.
47S rRNA real-time reverse transcription-PCR. Levels of 47S rRNA transcripts were determined as described previously by Cui and Tseng (10). Briefly, total RNA was reverse transcribed with a mouse rRNA-specific primer (5'-CGTGGCATGAACACTTGG-3'). Real-time PCR was performed with iQ SYBR Green Supermix (Bio-Rad) according to the manufacturer's protocol, with the forward primer 5'-CTGACACGCTGTCCTTTCCC-3' and the reverse primer 5'-GTGAGCCGAAATAAGGTGGC-3' on an iCycler thermal cycler (Bio-Rad). The absolute copy number was obtained by comparison to serial dilutions of a known amount of plasmid containing the mouse rDNA repeat.
rRNA labeling experiments. Equal numbers of wild-type and Arf–/– MEFs were starved in methionine-free media containing 10% dialyzed fetal bovine serum. For uridine labeling, cells were labeled in medium containing 2.5 µCi/ml [3H]uridine (Amersham) and then chased in label-free medium. Where noted, cells were treated with 50 µCi/ml [methyl-3H]methionine (Amersham) for 30 min and chased in unlabeled methionine-containing (10 µM) media in the nuclear/cytoplasmic fractionation experiments. Total RNA was isolated using Trizol reagent (Invitrogen) and loaded onto 1% agarose-formaldehyde gels for the uridine experiments. Cellular fractionation was carried out using a nuclear extraction kit according to the manufacturer's protocol (Active Motif). Total RNA was isolated from the nuclear and cytoplasmic fractions using Trizol and loaded onto 1% agarose-formaldehyde gels. RNA was transferred to Hybond N+ membranes (Amersham), cross-linked, sprayed with En3Hance (Perkin-Elmer), and subjected to autoradiography.
| RESULTS |
|---|
|
|
|---|
|
|
|
|
|
We first determined whether the proliferation rates varied between wild-type and Arf–/– BMM, osteoclast precursors. BrdU labeling of BMMs demonstrated no significant differences in the proliferation rates between wild-type and Arf–/– osteoclast precursors (Fig. 6A), similar to the equal proliferation rates of early passage MEFs (Fig. 3B). Next, BMMs from Arf–/– and wild-type mice were induced to produce mature osteoclasts by the addition of macrophage colony-stimulating factor (M-CSF) and RANKL. After 3 days of stimulation with RANKL, cells were fixed and stained with a TRAP substrate, an osteoclast-specific stain that relies on the abundance of TRAP protein produced by the osteoclast. An increased number of mature osteoclasts derived from the Arf–/– precursors was observed compared to that of the wild-type controls (Fig. 6B). TRAP-positive cells with greater than five nuclei were counted as a way to differentiate maturing osteoclasts from immature precursors and resulted in a significant increase in the Arf–/– genotype (149 versus 91 per well; n = 5; P = 0.01) (Fig. 6C).
|
Loss of Arf increases rRNA transcription, rRNA processing, and ribosome nuclear export. Previous reports have demonstrated a role for ARF in rRNA processing (37). Furthermore, our laboratory has previously demonstrated ARF's inhibitory activity on the shuttling of NPM (8) and NPM's nucleolar cargo, rpL5 and 5S rRNA (46). Additional reports have demonstrated a role for nucleolar ARF in preventing rDNA transcription through both Myc-dependent and -independent mechanisms (2, 3, 30). Taken together, nucleolar ARF could prevent all three steps in ribosome biogenesis: transcription, processing, and export. The loss of Arf had no impact on the levels of either NPM or rpL5, suggesting that ARF's effect on this pathway was not due to altered synthesis and/or destruction of these proteins (Fig. 7A). Moreover, serial immunodepletion of NPM revealed two distinct pools of ARF: one that is effectively associated with NPM (Fig. 7B, lane 1) and a second pool that is free from NPM (Fig. 7B, lane 6). This implies that ARF's effects on ribosome biogenesis may not be relegated to only NPM-dependent processes and is consistent with the idea that ARF antagonizes rDNA transcription through other unique, physically interacting proteins. Accordingly, the loss of Arf resulted in a fourfold increase in 47S rRNA transcription (Fig. 7C), a process thought to be independent of direct NPM regulation (as NPM does not localize to the fibrillar compartment of the nucleolus).
|
To determine the precise step at which ARF might influence rRNA processing, we labeled cells with [methyl-3H]methionine, which labels rRNA, and loaded equal amounts of the radioactive label to examine processing intermediates after short time periods of chase with label-free media. We observed only a modest increase of the 32S rRNA precursors in cells lacking Arf at early time periods, indicating that ARF may interfere with the processing steps between the 47S transcript and the 32S intermediate (Fig. 7E). However, after 2 h of chase, we saw no differences in the relative amounts of radioactivity in the final 18S and the 28S products, indicating that the loss of Arf had no impact on these downstream processing steps. These results exactly mirror what Sugimoto and colleagues observed when they overexpressed ARF, namely, an accumulation of improperly processed rRNA intermediates between the 47S and 32S stages (37), albeit to a far lesser extent in our experiments.
As a final step in ribosome biogenesis, mature ribosome subunits are exported to the cytosol in a process that we have previously attributed to NPM-directed nuclear export (27, 46). The Arf-null MEFs exhibited a more robust (
25-fold) nuclear export of newly processed rRNAs than the wild-type cells did (Fig. 8A). Again, this extreme difference between the wild-type and the Arf-null cells was far greater than any previous step in ribosome biogenesis (e.g., transcription or processing), implying that each step represents an amplification of the previous step. This was most evident when the real-time nuclear export of rRNAs, as monitored by scintillation counting of newly exported 3H-labeled rRNA, revealed that the absolute rates of rRNA export were threefold increased in cells lacking Arf (Fig. 8B). Taking these data together, we believe this reflects the ability of ARF to regulate moment-to-moment steps in ribosome biogenesis, such that alterations in ARF levels may produce robust and rapid responses that effect cytoplasmic ribosomal content.
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
In the past few years, numerous p53-independent functions have been ascribed to ARF (35). We found that nearly half of the basal ARF in the cell is in a complex with NPM, a protein previously shown to interact with human and mouse ARF proteins (4, 8, 21). While much of the work concerning the ARF-NPM interaction has focused on the ability of each protein to antagonize the function of the other (4, 8, 21, 24, 46), our findings suggest that the baseline interaction functions to maintain a controlled level of ribosome biogenesis. We propose a model where basal ARF antagonizes a small pool of NPM, either directly or enzymatically (8, 38), and thereby constantly limits ribosome output from the nucleolus. Importantly, levels of NPM did not change in the absence of ARF, but rather NPM activity was greatly increased as measured by its ability to promote ribosome nuclear export. Consistent with this model, the knockdown of basal NPM proteins resulted in dramatic reductions in protein production independent of cell proliferation, again underscoring the need for a consistent level of "ARF-free" NPM to promote ribosome synthesis.
While the mechanism and nature of such inhibition are still unclear, our data are consistent with a "thermostat" function for ARF, in that small changes in the abundance of ARF cause its binding partners to either dampen or enhance ribosome synthesis and export and, ultimately, lead to global changes in protein synthesis. It is apparent from our data that basal ARF can act in three distinct steps: (i) rDNA transcription, (ii) rRNA processing, and (iii) rRNA nuclear export.
While NPM has been ascribed roles in both rRNA processing and nuclear export (36, 47), we are uncertain of its ability to regulate rDNA transcription. In fact, NPM and ARF are both found in the granular region of the nucleolus, relatively far removed from the sites of nucleolar rDNA transcription (8). However, we did observe significantly enhanced transcription of 47S rRNA in the absence of Arf, implying that ARF proteins might regulate this process either directly or indirectly. This is not unprecedented, given recent findings that human ARF interacts with topoisomerase I to inhibit rDNA transcription (3, 23). Additionally, nearly half of the basal ARF protein is not bound to NPM, and we therefore cannot rule out the possibility that this pool of ARF is bound to proteins involved in rDNA transcription.
We suggest that ARF is expressed at a low level in interphase cells to ensure that proper growth control is achieved. This would serve to keep the cell in metabolic check, preventing the cell from wasting energy on unnecessary protein synthesis. Disruption of this exquisite basal ARF control would then have a twofold effect: (i) cells would produce far too many ribosomes, resulting in tremendous gains in protein synthesis, and (ii) the resultant cells would be highly susceptible to oncogenic signals. This setting would seem to provide a selective advantage to premalignant cells by ramping up their growth and, in the presence of appropriate signals, their proliferation. In support of this hypothesis, a recent study on the methylation of key loci involved in colorectal carcinogenesis demonstrated that 32% of the adenomas (premalignant lesions) isolated from patients with sporadic colorectal cancer demonstrated abnormalities at the Arf locus (11). Our findings represent a novel and important role for basal ARF in maintaining protein synthetic homeostasis in nonmalignant cells. While NPM is certainly required for much of the ribosome biogenesis gains observed for Arf-deficient cells, other interesting nucleolar targets of basal ARF must certainly exist. Precise details of how they may be affected remain elusive. Understanding the nucleolar integration of disparate requirements for proliferation, growth, and ribosome biogenesis will deepen our knowledge of how proteins like ARF adapted from regulators of cellular homeostasis to bona fide tumor suppressors.
| ACKNOWLEDGMENTS |
|---|
A.J.A. is a recipient of a grant-in-aid from the Department of Defense Breast Cancer Research Program (BC030793). L.B.M. is supported by the Department of Defense Prostate Cancer Research Program award number W81XWH-04-0909. A.J.S. and M.K. are supported by the Siteman Cancer Biology Pathway. J.D.W. thanks the Pew Charitable Trusts and is a recipient of grants-in-aid from the Susan G. Komen for the Cure and National Institutes of Health (GM066032).
| FOOTNOTES |
|---|
Published ahead of print on 10 December 2007. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Ayrault, O., L. Andrique, D. Fauvin, B. Eymin, S. Gazzeri, and P. Seite. 2006. Human tumor suppressor p14ARF negatively regulates rRNA transcription and inhibits UBF1 transcription factor phosphorylation. Oncogene 25:7577-7786.[CrossRef][Medline]
3. Ayrault, O., L. Andrique, C. J. Larsen, and P. Seite. 2004. Human Arf tumor suppressor specifically interacts with chromatin containing the promoter of rRNA genes. Oncogene 23:8097-8104.[CrossRef][Medline]
4. Bertwistle, D., M. Sugimoto, and C. J. Sherr. 2004. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol. Cell. Biol. 24:985-996.
5. Bertwistle, D., F. Zindy, C. J. Sherr, and M. F. Roussel. 2004. Monoclonal antibodies to the mouse p19(Arf) tumor suppressor protein. Hybrid. Hybridomics 23:293-300.[CrossRef][Medline]
6. Birnstiel, M. L., M. I. Chipchase, and B. B. Hyde. 1963. The nucleolus, a source of ribosomes. Biochim. Biophys. Acta 76:454-462.[Medline]
7. Boon, K., H. N. Caron, R. van Asperen, L. Valentijn, M. C. Hermus, P. van Sluis, I. Roobeek, I. Weis, P. A. Voute, M. Schwab, and R. Versteeg. 2001. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J. 20:1383-1393.[CrossRef][Medline]
8. Brady, S. N., Y. Yu, L. B. Maggi, Jr., and J. D. Weber. 2004. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol. Cell. Biol. 24:9327-9338.
9. Ciarmatori, S., P. H. Scott, J. E. Sutcliffe, A. McLees, H. M. Alzuherri, J. H. Dannenberg, H. te Riele, I. Grummt, R. Voit, and R. J. White. 2001. Overlapping functions of the pRb family in the regulation of rRNA synthesis. Mol. Cell. Biol. 21:5806-5814.
10. Cui, C., and H. Tseng. 2004. Estimation of ribosomal RNA transcription rate in situ. BioTechniques 36:134-138.[Medline]
11. Esteller, M., S. Tortola, M. Toyota, G. Capella, M. A. Peinado, S. B. Baylin, and J. G. Herman. 2000. Hypermethylation-associated Inactivation of p14ARF is independent of p16INK4a methylation and p53 mutational status. Cancer Res. 60:129-133.
12. Fingar, D. C., and J. Blenis. 2004. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23:3151-3171.[CrossRef][Medline]
13. Fromont-Racine, M., B. Senger, C. Saveanu, and F. Fasiolo. 2003. Ribosome assembly in eukaryotes. Gene 313:17-42.[CrossRef][Medline]
14. Gil, J., and G. Peters. 2006. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat. Rev. Mol. Cell. Biol. 7:667-677.[CrossRef][Medline]
15. Grandori, C., N. Gomez-Roman, Z. A. Felton-Edkins, C. Ngouenet, D. A. Galloway, R. N. Eisenman, and R. J. White. 2005. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat. Cell Biol. 7:311-318.[CrossRef][Medline]
16. Grewal, S. S., L. Li, A. Orian, R. N. Eisenman, and B. A. Edgar. 2005. Myc-dependent regulation of ribosomal RNA synthesis during Drosophila development. Nat. Cell Biol. 7:295-302.[CrossRef][Medline]
17. Hannan, K. M., R. D. Hannan, S. D. Smith, L. S. Jefferson, M. Lun, and L. I. Rothblum. 2000. Rb and p130 regulate RNA polymerase I transcription: Rb disrupts the interaction between UBF and SL-1. Oncogene 19:4988-4999.[CrossRef][Medline]
18. Hernandez-Verdun, D., and P. Roussel. 2003. Regulators of nucleolar functions. Prog. Cell Cycle Res. 5:301-308.[Medline]
19. Inoue, K., M. F. Roussel, and C. J. Sherr. 1999. Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc. Natl. Acad. Sci. USA 96:3993-3998.
20. Inoue, K., R. Wen, J. E. Rehg, M. Adachi, J. L. Cleveland, M. F. Roussel, and C. J. Sherr. 2000. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. Genes Dev. 14:1797-1809.
21. Itahana, K., K. P. Bhat, A. Jin, Y. Itahana, D. Hawke, R. Kobayashi, and Y. Zhang. 2003. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol. Cell 12:1151-1164.[CrossRef][Medline]
22. Kamijo, T., F. Zindy, M. F. Roussel, D. E. Quelle, J. R. Downing, R. A. Ashmun, G. Grosveld, and C. J. Sherr. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91:649-659.[CrossRef][Medline]
23. Karayan, L., J. F. Riou, P. Seite, J. Migeon, A. Cantereau, and C. J. Larsen. 2001. Human ARF protein interacts with topoisomerase I and stimulates its activity. Oncogene 20:836-848.[CrossRef][Medline]
24. Korgaonkar, C., J. Hagen, V. Tompkins, A. A. Frazier, C. Allamargot, F. W. Quelle, and D. E. Quelle. 2005. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol. Cell. Biol. 25:1258-1271.
25. Maggi, L. B., Jr., and J. D. Weber. 2005. Nucleolar adaptation in human cancer. Cancer Investig. 23:599-608.[CrossRef][Medline]
26. Moss, T. 2004. At the crossroads of growth control; making ribosomal RNA. Curr. Opin. Genet. Dev. 14:210-217.[CrossRef][Medline]
27. Pelletier, C. L., L. B. Maggi, Jr., S. N. Brady, D. K. Scheidenhelm, D. H. Gutmann, and J. D. Weber. 2007. TSC1 sets the rate of ribosome export and protein synthesis through nucleophosmin translation. Cancer Res. 67:1609-1617.
28. Pich, A., L. Chiusa, and E. Margaria. 2000. Prognostic relevance of AgNORs in tumor pathology. Micron 31:133-141.[CrossRef][Medline]
29. Pomerantz, J., N. Schreiber-Agus, N. J. Liegeois, A. Silverman, L. Alland, L. Chin, J. Potes, K. Chen, I. Orlow, H. W. Lee, C. Cordon-Cardo, and R. A. DePinho. 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723.[CrossRef][Medline]
30. Qi, Y., M. A. Gregory, Z. Li, J. P. Brousal, K. West, and S. R. Hann. 2004. p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 431:712-717.[CrossRef][Medline]
31. Ries, S., C. Biederer, D. Woods, O. Shifman, S. Shirasawa, T. Sasazuki, M. McMahon, M. Oren, and F. McCormick. 2000. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 103:321-330.[CrossRef][Medline]
32. Ritossa, F. M., and S. Spiegelman. 1965. Localization of DNA complementary to ribosomal RNA in the nucleolus organizer region of Drosophila melanogaster. Proc. Natl. Acad. Sci. USA 53:737-745.
33. Rubbi, C. P., and J. Milner. 2003. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 22:6068-6077.[CrossRef][Medline]
34. Ruggero, D., and P. P. Pandolfi. 2003. Does the ribosome translate cancer? Nat. Rev. Cancer 3:179-192.[CrossRef][Medline]
35. Sherr, C. J. 2006. Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 6:663-673.[CrossRef][Medline]
36. Spector, D. L., R. L. Ochs, and H. Busch. 1984. Silver staining, immunofluorescence, and immunoelectron microscopic localization of nucleolar phosphoproteins B23 and C23. Chromosoma 90:139-148.[CrossRef][Medline]
37. Sugimoto, M., M. L. Kuo, M. F. Roussel, and C. J. Sherr. 2003. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol. Cell 11:415-424.[CrossRef][Medline]
38. Tago, K., S. Chiocca, and C. J. Sherr. 2005. Sumoylation induced by the Arf tumor suppressor: a p53-independent function. Proc. Natl. Acad. Sci. USA 102:7689-7694.
39. Tao, W., and A. J. Levine. 1999. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. USA 96:6937-6941.
40. Tapon, N., K. H. Moberg, and I. K. Hariharan. 2001. The coupling of cell growth to the cell cycle. Curr. Opin. Cell Biol. 13:731-737.[CrossRef][Medline]
41. Teitelbaum, S. L., and F. P. Ross. 2003. Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4:638-649.[CrossRef][Medline]
42. Trere, D. 2000. AgNOR staining and quantification. Micron 31:127-131.[CrossRef][Medline]
43. Voit, R., K. Schafer, and I. Grummt. 1997. Mechanism of repression of RNA polymerase I transcription by the retinoblastoma protein. Mol. Cell. Biol. 17:4230-4237.[Abstract]
44. Weber, J. D., M. L. Kuo, B. Bothner, E. L. DiGiammarino, R. W. Kriwacki, M. F. Roussel, and C. J. Sherr. 2000. Cooperative signals governing ARF-Mdm2 interaction and nucleolar localization of the complex. Mol. Cell. Biol. 20:2517-2528.
45. Weber, J. D., L. J. Taylor, M. F. Roussel, C. J. Sherr, and D. Bar-Sagi. 1999. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell. Biol. 1:20-26.[CrossRef][Medline]
46. Yu, Y., L. B. Maggi, Jr., S. N. Brady, A. J. Apicelli, M. S. Dai, H. Lu, and J. D. Weber. 2006. Nucleophosmin is essential for ribosomal protein L5 nuclear export. Mol. Cell. Biol. 26:3798-3809.
47. Yung, B. Y., R. K. Busch, H. Busch, A. B. Mauger, and P. K. Chan. 1985. Effects of actinomycin D analogs on nucleolar phosphoprotein B23 (37,000 daltons/pI 5.1). Biochem. Pharmacol. 34:4059-4063.[CrossRef][Medline]
48. Zhai, W., and L. Comai. 2000. Repression of RNA polymerase I transcription by the tumor suppressor p53. Mol. Cell. Biol. 20:5930-5938.
49. Zhao, H., H. Kitaura, M. S. Sands, F. P. Ross, S. L. Teitelbaum, and D. V. Novack. 2005. Critical role of beta3 integrin in experimental postmenopausal osteoporosis. J. Bone Miner. Res. 20:2116-2123.[CrossRef][Medline]
50. Zindy, F., C. M. Eischen, D. H. Randle, T. Kamijo, J. L. Cleveland, C. J. Sherr, and M. F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12:2424-2433.
51. Zindy, F., R. T. Williams, T. A. Baudino, J. E. Rehg, S. X. Skapek, J. L. Cleveland, M. F. Roussel, and C. J. Sherr. 2003. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc. Natl. Acad. Sci. USA 100:15930-15935.
| ||||||